EcoDrugPlus

Purinergic Receptor P2y2

Ensembl ID : ENSNBRG00000000082
Gene Symbol: P2RY2
3 Cross references
197 Possible Orthologues:

Putative Mediator Of Rna Polymerase Ii Transcription Subunit 26-Like

Ensembl ID : ENSNBRG00000012478
Gene Symbol: LOC102788001
2 Cross references
190 Possible Orthologues:

Pyrimidinergic Receptor P2y4

Ensembl ID : ENSNBRG00000022466
Gene Symbol: P2RY4
4 Cross references
165 Possible Orthologues:

Pyrimidinergic Receptor P2y6

Ensembl ID : ENSNBRG00000013996
Gene Symbol: P2RY6
2 Cross references
182 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSNBRG00000019088
Gene Symbol: RAMP1
3 Cross references
184 Possible Orthologues:

Receptor Activity Modifying Protein 1

Ensembl ID : ENSNBRG00000014858
Gene Symbol: RAMP1
2 Cross references
191 Possible Orthologues:

Receptor Tyrosine-Protein Kinase Erbb-2-Like

Ensembl ID : ENSNBRG00000011460
Gene Symbol: LOC102792525
3 Cross references
200 Possible Orthologues:

Receptor Tyrosine-Protein Kinase Erbb-4-Like

Ensembl ID : ENSNBRG00000019036
Gene Symbol: LOC102787686
3 Cross references
230 Possible Orthologues:

Receptor-Interacting Serine/threonine-Protein Kinase 1-Like

Ensembl ID : ENSNBRG00000012956
Gene Symbol: LOC102783472
3 Cross references
197 Possible Orthologues:

Regulatory Associated Protein Of Mtor Complex 1

Ensembl ID : ENSNBRG00000017604
Gene Symbol: RPTOR
3 Cross references
213 Possible Orthologues:

Renin-Like

Ensembl ID : ENSNBRG00000017285
Gene Symbol: LOC102787088
3 Cross references
219 Possible Orthologues:

Retinoic Acid Receptor Rxr-Alpha-A-Like

Ensembl ID : ENSNBRG00000011679
Gene Symbol: LOC102786191
3 Cross references
225 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).